Dr. Zhehai Wang 王哲海
Chief Physician, Research Professor
Department of Respiratory Medicine, Ward 2, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and medical treatment of tumors, including chronobiological chemotherapy for malignant tumors.
Dr. Wang is a Chief Physician and Researcher at Shandong Cancer Hospital. Graduating from Qingdao University Medical College in 1985, Dr. Wang trained in Japan and earned a master's degree from Shandong University in 2004. With over 20 years in medical oncology, Dr. Wang has led clinical trials, published over 70 papers, and authored books on chemotherapy adverse reactions and tumor metastasis.
Professional roles
- Chair, Chemotherapy Branch, Shandong Anti-Cancer Association
- Member, Chinese Society of Clinical Oncology (CSCO)
- Member, CSCO Expert Group on Tumor Nutrition Therapy
- Editorial Board Member, International Journal of Oncology
Name order: in Chinese the family name comes first (Wang Zhehai). Papers usually list the name as Zhehai Wang or Wang Z.
Selected publications
102 papers on PubMed matched by name and affiliation; 25 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Immunol, 2026 (senior author): Safety and efficacy of first-line iparomlimab and tuvonralimab (QL1706) plus carboplatin and etoposide in patients with extensive-stage small cell lung cancer: an open-label, single-arm, phase 2 trial (DUBHE-L-209). PubMed 42643500
- Front Pharmacol, 2026 (senior author): Real-world efficacy and safety of anlotinib in Chinese solid tumors patients with liver metastases: a multicenter retrospective study. PubMed 42222141
- Signal Transduct Target Ther, 2024 (senior author): Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: a phase II clinical trial. PubMed 39278918
- Oncol Lett, 2024 (senior author): Efficacy and survival outcomes of alectinib vs. crizotinib in ALK‑positive NSCLC patients with CNS metastases: A retrospective study. PubMed 38586212
- J Cancer Res Clin Oncol, 2024 (senior author): Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis. PubMed 38280966
- Cancer Sci, 2023 (senior author): Molecular subtyping of small-cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies. PubMed 36178064
- Lung Cancer, 2021 (senior author): PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab. PubMed 33246647
- Thorac Cancer, 2020 (senior author): Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review. PubMed 32833320
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion